ReviewRespiratory research2020
Measuring disease activity in COPD: is clinically important deterioration the answer?
Review in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement.International journal of chronic obstructive pulmonary disease · 2023Pooled it
- Identifying patients with mild-to-moderate COPD who require intensified initial treatment to control annualized clinically important deterioration.NPJ primary care respiratory medicine · 2026Trial
- Clinical impact of disease stability on exacerbation and mortality in COPD: a retrospective cohort study.Annals of medicine · 2026Article
- Identification of clinical phenotypes and development of a predictive model for rapid lung function decline in COPD patients.Annals of medicine · 2026Article
- Clinically important deterioration in a mild-moderate COPD population.ERJ open research · 2025Article
- Clinically Important Improvements and Disease Stability with Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy in the ELLITHE Trial: A Post Hoc Responder Analysis.Pulmonary therapy · 2025Article
- Treatment needs in mild-to-moderate chronic obstructive pulmonary disease: evidence from longitudinal studies.Journal of thoracic disease · 2025Article
- Is Disease Stability an Attainable Chronic Obstructive Pulmonary Disease Treatment Goal?American journal of respiratory and critical care medicine · 2025Review
- What is worth measuring in patients with COPD?Multidisciplinary respiratory medicine · 2025Article
- Diffusion capacity and static hyperinflation as markers of disease progression predict 3-year mortality in COPD: Results from COSYCONET.Respirology (Carlton, Vic.) · 2025Observational
- Two-year Results of Bronchoscopic Lung Volume Reduction Using One-Way Endobronchial Valves: Real-World Single Center Data.International journal of chronic obstructive pulmonary disease · 2025Article
- Impact of Pulmonary Hypertension on Posttransplant Survival of Patients With Pulmonary Fibrosis at High Altitude: A Prospective Cohort Study.Canadian respiratory journal · 2025Article
- The DOSE index in chronic obstructive pulmonary disease: evaluating healthcare costs.BMC pulmonary medicine · 2024Article
- Any Decrease in Lung Function is Associated With Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional Trial.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Lung Inflammation in alpha-1-antitrypsin deficient individuals with normal lung function.Respiratory research · 2023Article
- Relationship between serum Th1/Th2 imbalance and depression in elderly patients with COPD and its clinical implications.Technology and health care : official journal of the European Society for Engineering and Medicine · 2023Article
- Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward.American journal of respiratory and critical care medicine · 2022Review
- Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?Respiratory research · 2021Article
- Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.NPJ primary care respiratory medicine · 2021Review
- Future concepts in bronchodilation for COPD: dual-European respiratory review : an official journal of the European Respiratory Society · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Given the heterogeneity of chronic obstructive pulmonary disease (COPD), personalized clinical management is key to optimizing patient outcomes. Important treatment goals include minimizing disease activity and preventing disease progression; however, quantification of these components remains a challenge. Growing evidence suggests that decline over time in forced expiratory volume in 1 s (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.